Guatemala becomes the fourth country to eliminate river blindness

Story: 2016 C.E.  |  Last updated: January 1, 2016

In September 2016 C.E., the Pan American Health Organization declared Guatemala free of onchocerciasis — a parasitic disease that had threatened the sight and livelihoods of hundreds of thousands of people, most of them living in rural, agricultural communities near fast-moving rivers.

Key facts

• River blindness elimination: Guatemala was certified free of onchocerciasis in 2016 C.E., joining Colombia, Ecuador, and Mexico — all of which achieved elimination between 2013 C.E. and 2015 C.E.
• Ivermectin distribution: The country’s core strategy was twice-yearly mass treatment with the antiparasitic drug Mectizan® (ivermectin), reaching at least 85% of the eligible population for up to 12 years.
• Disease burden in Guatemala: Of six affected countries in the Americas, Guatemala carried the heaviest load — four separate transmission foci and roughly 41% of the 568,000 people at risk across the region.

What onchocerciasis actually does

Onchocerciasis is caused by a parasitic worm called Onchocerca volvulus, transmitted through the bite of black flies that breed in fast-flowing rivers and streams. In Guatemala, these are called “canche” flies, and they thrive in the agricultural river valleys where many rural and Indigenous communities depend on the land for survival.

Repeated infections lead to intense itching, skin damage, and — in the worst cases — irreversible blindness. The disease disproportionately affects people in poverty, both because of where the flies breed and because limited healthcare access means infections go untreated for years.

In Guatemala, the disease carries a local name that honors the physician who first described it in the Americas: “Robles disease,” named after Dr. Rodolfo Robles. In 1915 C.E., Robles established the causal link between the parasitic infection and its visual effects — building on earlier descriptions from Africa and placing Guatemalan science on the global map of tropical medicine.

Two decades of community-level work

Guatemala’s elimination was not a single intervention. It was the result of more than 20 years of sustained, coordinated effort — one that required deep trust between health workers and the communities they served.

The strategy centered on periodic mass drug administration. Twice each year, health workers and community volunteers traveled to affected areas, calibrating doses of Mectizan® to each recipient’s weight and height. The goal was to interrupt transmission entirely — not just treat individual cases, but deprive the worm of the human host density it needs to keep spreading.

That kind of population-level coverage — consistently reaching 85% or more of eligible people — required genuine community buy-in. As Guatemala’s Minister of Health, Lucrecia Hernández Mack, noted at the announcement, elimination was made possible in large part by “the high level of participation and empowerment of affected communities.”

The Pan American Health Organization (PAHO), the Carter Center’s Onchocerciasis Elimination Program for the Americas (OEPA), and Merck’s Mectizan® Donation Program provided technical support, funding, and drug supply throughout. The drug donation program — in which Merck has provided ivermectin free of charge since 1987 C.E. — is one of the longest-running pharmaceutical donation programs in history.

Lasting impact

Guatemala’s certification matters beyond its borders. It brings the Americas closer to becoming the first region in the world to eliminate onchocerciasis entirely. The remaining transmission focus lies in Amazonian communities along the Brazil-Venezuela border — and the region’s track record now shows that elimination is achievable even in complex, geographically difficult settings.

The tools and institutional relationships built through the Americas program have also informed global efforts. The World Health Organization’s broader onchocerciasis elimination roadmap — which covers endemic countries across sub-Saharan Africa — draws on lessons from the Americas, including community-directed treatment models that put local health workers at the center of delivery.

For Guatemala itself, elimination lifts a real constraint on human potential. Blindness and disability in working-age adults affects entire households and communities. Removing a preventable cause of both creates conditions for health, economic participation, and a different kind of future.

Blindspots and limits

Guatemala’s success depended heavily on long-term external support — from international organizations, a pharmaceutical donation program, and sustained foreign funding. Whether lower-income countries facing similar disease burdens can replicate this model without comparable external backing remains an open question.

The Americas region also still has unfinished work: the Yanomami and Ye’kwana communities along the Brazil-Venezuela border continue to face active transmission, with elimination efforts in that area complicated by geography, political tensions, and access constraints. The celebration in Guatemala is real — but the region is not yet done.

Read more

For more on this story, see: Pan American Health Organization (PAHO)

For more from Good News for Humankind, see:

• Global suicide rate has fallen by 40% since 1995
• U.K. cancer death rates down to their lowest level on record
• The Good News for Humankind archive on global health

About this article

• 🤖 This article is AI-generated, based on a framework created by Peter Schulte.
• 🌍 It aims to be inspirational but clear-eyed, accurate, and evidence-based, and grounded in care for the Earth, peace and belonging for all, and human evolution.
• 💬 Leave your notes and suggestions in the comments below — I will do my best to review and implement where appropriate.
• ✉️ One verified piece of good news, one insight from Antihero Project, every weekday morning. Subscribe free.